Select Date
- >
Loading available days...
Available Slots:
Overview
Dr. Animesh Saha is a highly experienced Medical Oncologist based in Kolkata, West Bengal, with over 13 years of dedicated practice in the field of oncology. He holds an impressive array of qualifications, including FRCR (London), MD in Radiation Oncology, DNB in Radiation Oncology, CESR (UK), PGCME (Dundee), and MNAMS. He also completed his MBBS and is recognized as a PDCR professional. His extensive educational background equips him with the knowledge and expertise to deliver exceptional care to his patients.
Dr. Saha has previously served as a Consultant at the Leeds Cancer Centre in the UK, where he honed his skills in treating various types of cancer. His expertise extends to both common and rare oncological conditions, making him a valuable resource for patients seeking specialized care. He is committed to staying updated with the latest advancements in oncology, ensuring that his patients receive the best possible treatment options available.
Fluent in English, Hindi, and Bengali, Dr. Saha provides a comfortable communication environment for his diverse patient population, fostering a supportive and understanding space for discussing health concerns and treatment plans. His approach is patient-centered, emphasizing the importance of individualized care tailored to meet each patient's unique needs.
As an exclusive partner in the medical community, Dr. Animesh Saha continues to make a significant impact in the lives of those battling cancer, helping them navigate their journey with compassion and expertise. His dedication and commitment to his profession and patients have earned him respect and recognition in the field of Medical Oncology.
Experience
- Consultant Clinical Oncologist Apollo Gleneagles Hospitals, Kolkata from Nov 2019 Till now
- Consultant Clinical Oncologist Leeds Cancer Centre, UK, NHS trust from Nov 2018- Nov 2019
- Specialist registrar Leeds Cancer Centre, UK, NHS trust from March 2017 Nov 2018
- Clinical Oncology Fellow Tata Medical Center, Kolkata June 2013 to Jan 2017
- Post Graduate trainee IPGME&R and SSKM hospital, Kolkata June 2010 to June 2013
Memberships
Certification
- Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
- Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
- FRCR in Clinical Oncology, Awarding body Royal College of Radiologists, April 2018.
- Professional diploma in clinical research awarded by Catalyst Clinical Services Pvt. Ltd, India, August,2014.
- DNB Radiotherapy awarded by National Board of Examinations, India in June,2014
- MD Radiotherapy awarded by The West Bengal University of Health Sciences in April 2014.
- M.B.B.S awarded by The West Bengal University of Health Sciences in November,2009
Professional Memberships
- Indian medical association (life member no- BGL/9348/119/305/161892/2011-12/L)
- Association of radiation oncologists of India ( life member no- 1672)
- European society of medical oncology (ESMO ID- 81560).
- Royal College of Radiologists (Membership no: 315972)
- European Society for Radiotherapy and Oncology (Membership no-24697)
- Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
Awards
- Certificate of Eligibility for Specialist Registration (CESR), UK awarded by General Medical Council, UK in October 2019.
- He received Cyclotron Trust Award with travel grant to attend the Education Sessions of PTCOG-58 conference held in Manchester, United Kingdom between 10–15 June, 2019.
- He was selected for ESMO preceptorship on Head & Neck cancer which was held in Zurich, Switzerland between May, 2019.
- Having qualified for the award of Diplomate of the National Board of Examinations in Radiotherapy at the examination held in December, 2013; he has been admitted by the council as member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018.
- International training fellowship in St James University Hospital (Leeds Teaching Hospital), UK from March 2017–October 2018.
- Fellowship in Clinical Oncology from Tata Medical Center, Kolkata, India from June, 2013 to January, 2017.
- He was selected for ESMO preceptorship on Brain Tumor held between September 28, 2018–September 29, 2018 in Athens, Greece.
- FRCR in Clinical Oncology awarded by Royal College of Radiologists in April, 2018.
- Hypo-fractionated radiotherapy schedule of 35Gy in 10 fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in Controversies in Clinical Oncology, which was held in Kolkata, India in 2016.
- He had an oral presentation in The Royal College of Radiologists proffered paper session in NCRI Conference 2015, Liverpool, UK; for which he got ‘The Company of Biologists Travel Award’.
- ‘Is daily MVCT imaging really required in helical tomotherapy for head and neck cancers?: An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata, India.
Research and Publication
Dr Saha has participated as a sub investigator in many international trials. Some of the trials are-
- A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
- Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (ABC07 trial)
- A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE trial)
- ETOP/IFCT 4-12 STIMULI trial which is an Open-label, randomised, two-arm, phase II trial looking into addition of Immunotherapy with Nivolumab and Ipilumumab to standard of care in limited stage Small cell lung carcinoma.
- A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
- GO40241 Phase III randomized, double-blind, placebo-controlled study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
- Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer: A randomised phase III trial (SARON study)
- A multi-centre randomised study of induction chemotherapy followed by capecitabine(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP 2 study)
- A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma. (SYSTEM 2 trial).
- A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
- A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006).
- Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study).
- Adjuvant Durvalumab following sequential chemotherapy and radiotherapy in patients with unresecatble stage III NSCLC (PACIFIC 6 study).
Dr Saha has numerous publications in national and international peer reviewed journals. Some of his publications include-
- Can Dosimetry Affect Overall Survival in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)? An Analysis of 1300 Patients.
- Setting up a lung Stereotactic Body Radiotherapy (SBRT) service in a tertiary centre in eastern India– The process, quality assurance and early experience.
- Radical radiotherapy or chemoradiotherapy for inoperable locally advanced non-small-cell lung cancer (NSCLC) - Analysis of patient profile, treatment approaches and outcomes of 213 patients at a tertiary cancer centre.
- A Prospective Study of an Offline Matching Protocol for Head and Neck Cancer on Helical Tomotherapy: The F5 Study.
- Acute toxicity and in-vivo dosimetry of a two week hypofractionated schedule within the HYPORT study.
- High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
- Quality Assurance and Acute Toxicities of a 2 Week Hypofractionated Palliative Radiotherapy Schedule used in a Prospective Phase I/II Study (HYPORT Study).
- Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of Large Number of Daily Imaging-based Corrections. Clin Oncol, 2016.
- Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
- Helical tomotherapy based intensity modulated radiotherapy for the management of difficult clinical situations in breast cancer.
- A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
Special Interests
- Lung cancer, Mesothelioma, Thymoma, Head & neck cancer, GI cancers (Esophageal cancer, Stomach Cancer, Liver cancer, Gall bladder cancer, Pancreas cancer, Cholangiocarcinoma, Small bowel cancer, Colon Cancer, Rectal cancer, Anal canal cancer),Adult CNS tumor (Brain & Spine tumor).
- Urology cancer ( Bladder, Prostate, Kidney cancer).
Videos
Frequently Asked Questions
Where does Dr. Animesh Saha practice?
Dr. Animesh Saha is a practicing physician at Apollo Multispecialty Hospitals. This hospital offers comprehensive healthcare services and is a leading provider of medical treatment.
Who is Dr. Animesh Saha?
Dr Animesh Saha is a renowned Oncologist with over 13 years of experience. He practices in Kolkata at Apollo Multispecialty Hospitals. Dr Animesh Saha holds a degree in MBBS, MD(Radiation Oncology), DNB(Radiation Oncology), MNAMS, PDCR, FRCR(London), CESR(UK), PGCME- Oncology (University of Dundee). Ex- Consultant Leeds Cancer Center, UK. He provides treatments including Chemotherapy, Radiation Therapy, Immunotherapy. He specializes in treating conditions like , Actinic keratosis, Cholangiocarcinoma.
Why do patients choose Dr. Animesh Saha?
Patients seek Dr. Animesh Saha's expertise in Intensity Modulated Radio Therapy (IMRT), Stereotactic Radio Therapy (SRT), and Breast Cancer Management. For a comprehensive overview of his services, please refer to his professional profile.
What is Dr. Animesh Saha's specialization?
Dr Animesh Saha specializes in Oncology. He has expertise in treating conditions such as , Actinic keratosis, Cholangiocarcinoma. His key treatments include Chemotherapy, Radiation Therapy, Immunotherapy.
What are Dr. Animesh Saha's medical qualifications?
Dr Animesh Saha holds MBBS, MD(Radiation Oncology), DNB(Radiation Oncology), MNAMS, PDCR, FRCR(London), CESR(UK), PGCME- Oncology (University of Dundee). Ex- Consultant Leeds Cancer Center, UK, reflecting his comprehensive education in the field of Oncology.
How many years of experience does Dr. Animesh Saha have?
Dr. Animesh Saha has 13 years of experience in oncology. His professional history spans various medical institutions.
What are Dr. Animesh Saha's credentials?
Dr. Animesh Saha holds an MBBS, MD in Radiotherapy, DNB in Radiotherapy, and is a Fellow of the Royal College of Radiologists, UK (FRCR). His expertise lies in Radiation Oncology.
